Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Medical and Pediatric Oncology

• Publication date

  2000-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/1096-911X(20001201)35:6<544::AID-MPO10>3.0.CO;2-2PMID 11107113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study.

  2000cited by this paper
• Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas

  1999cited by this paper
• Molecular biology of neuroblastoma.

  1999cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization

  1998cited by this paper
• Comparative genomic hybridization study of primary neuroblastoma tumors

  1997cited by this paper
• Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis.

  1997cited by this paper
• Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.

  1997cited by this paper

• Bioinformatics analysis of recurrent deletion regions in neuroblastoma

  2022cites this paper
• Circulating cell-free tumor DNA analysis in pediatric cancers.

  2020cites this paper
• Energy Metabolism and Metabolic Targeting of Neuroblastoma

  2019cites this paper
• Systematic computational identification of prognostic cytogenetic markers in neuroblastoma

  2019cites this paper
• Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification

  2019cites this paper
• The Effects of Hypoxic Preconditioning on the Oxygenation and Metabolic Profile of Neuroblastoma

  2018cites this paper
• Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition

  2017cites this paper
• Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.

  2013cites this paper
• Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

  2012cites this paper
• Neuroblastoma: The impact of biology and cooperation leading to personalized treatments

  2012cites this paper
• Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma.

  2011cites this paper
• DIPLOMARBEIT Heterogeneous MYCN amplification in neuroblastoma-amplicon , genomic background and genome instability

  2010cites this paper
• MOLECULAR MARKERS IN NEUROBLASTOMA

  2010cites this paper
• 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

  2010cites this paper
• Patología de los tumores neuroblásticos: evaluación pronóstica. Experiencia del centro español de referencia de la SEOP para estudios biopatológicos del neuroblastoma (1992-2005)

  2007cites this paper
• Perfil genómico del neuroblastoma de alto riesgo mediante hibridación genómica comparada

  2006cites this paper
• The two human homologues of yeast UFD2 ubiquitination factor, UBE4A and UBE4B, are located in common neuroblastoma deletion regions and are subject to mutations in tumours.

  2006cites this paper
• [Genomic profile in high risk neuroblastoma by comparative genomic hybridization].

  2006cites this paper
• The von Hippel‐Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma

  2006cites this paper
• Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

  2005cites this paper
• Fine mapping and evaluation of candidate genes for cervical cancer on 11q23

  2005cites this paper
• Characterization of karyotypic events and evolution in neuroblastoma

  2005cites this paper
• Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.

  2005cites this paper
• Expression of Platelet Derived Growth Factor Receptor-Beta ( PDGFR-β ) in phenotypically distinct human neuroblastoma cell lines

  2005cites this paper
• Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11

  2005cites this paper
• No evidence for involvement of SDHD in neuroblastoma pathogenesis

  2004cites this paper
• Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues.

  2004cites this paper
• Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.

  2004cites this paper
• Chemotherapy for neuroblastoma: is it all or none?

  2003cites this paper
• repp86 E xpression a nd O utcome i n P atients With N euroblastoma

  2003cites this paper
• Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2

  2003influential citation
• Repp86 expression and outcome in patients with neuroblastoma.

  2003cites this paper
• Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.

  2003cites this paper
• FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.

  2003cites this paper
• Proliferation marker KI‐S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification

  2002cites this paper
• Delineation of the heterogeneous pattern of genomic changes and identifacation of differentially expressed genes in neuroblastoma

  2002cites this paper
• Genetic parameters of neuroblastomas.

  2002cites this paper
• Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis

  2001cites this paper
• Neuroblastoma tumour genetics: clinical and biological aspects.

  2001cites this paper
• Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification

  2001cites this paper